Massachusetts Ballot to Decide on Psychedelics Legalization in November

LOS ANGELES- Massachusetts voters are set to decide on a significant measure this November with Question 4, a ballot initiative to legalize certain plant-based psychedelics, including psilocybin, mescaline, and dimethyltryptamine (DMT). If approved, Massachusetts would follow Oregon and Colorado in creating a regulated framework for adult psychedelic use, focusing on mental health applications.

Proponents argue that psychedelics offer therapeutic benefits for mental health conditions, such as PTSD and depression, citing recent studies and anecdotal evidence. The measure, supported by advocates like actress Eliza Dushku and mental health professionals, proposes regulated therapy centers where individuals over 21 could use psychedelics under supervision. The measure also permits limited home cultivation, allowing individuals to grow these substances in up to a 12-by-12-foot area within their homes. Supporters highlight that the proposal draws on therapeutic frameworks established in Oregon and Colorado, where early reports indicate minimal law enforcement issues tied to regulated psychedelics access​

However, the initiative faces strong opposition from groups like the Massachusetts Coalition for Safe Communities, which argues that the proposal lacks sufficient safeguards. Critics point to potential risks, such as increased public safety concerns related to accidental consumption and the absence of a community opt-out provision, which was included in Massachusetts’ earlier cannabis legislation. Opponents also raise concerns about commercialization, with predictions of high costs per therapy session, as seen in Oregon’s model​.

If passed, Question 4 would create a five-member state commission to oversee psychedelic use and regulate the therapeutic centers. A “Yes” vote would legalize access to these psychedelics within regulated settings, while a “No” vote would keep current laws unchanged.